MediciNova reports Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported top-line data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that up to

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE